Spanish Vaccine May Turn HIV Into A Minor Herpes-Like Chronic Infection

Friday, September 30th, 2011

A Phase I human study using a vaccine called MVA-B has achieved an immunological response in 92% of healthy volunteers against HIV, with 85% of them maintaining immunity for at least 12 months. Researchers from the Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Gregorio Marañón Hospital, Madrid and Clínic Hospital, ...

Diabetics That Visit Physicians More Frequently Have Improved Risk Factors

Thursday, September 29th, 2011

A report in the September 26 issue of Archives of Internal Medicine, one of the JAMA/Archives journals shows that diabetics who visit a primary care clinician twice a month have greater control of blood glucose, blood pressure and cholesterol levels. As per background information in the article, diabetes has ...

Some Physicians Feel They Have To Provide Too Much Care

Tuesday, September 27th, 2011

According to an investigation in the September 26 issue of Archives of internal Medicine, one of the JAMA/Archives journals, results from a survey of primary care physicians in the U.S. have revealed that several physicians believe their own patients are receiving too much medical care, and several believe that malpractice ...

Hip Fracture Linked With Increased Short-Term Death Rates For Some Older Women

Tuesday, September 27th, 2011

According to an investigation published Online First by Archives of Internal Medicine, one of JAMA/Archives journals, hip fracture is connected with an increase in short-term mortality (death within one year) for women between the ages of 65 to 79 years and for healthy women aged 80 years and over, however ...

Custirsen For Treatment Of Prostate Cancer – Publication Of Phase II Clinical And Pre-Clinical Data Announced

Thursday, September 8th, 2011

The September issue of the journals Clinical Cancer Research and Cancer Research published OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announcement of new data from its Phase II clinical and a pre-clinical study of custirsen (OGX-011/TV-1011), a drug that inhibits the production of clusterin, which is a protein commonly over-produced in cancer ...